The plain-language read
The uncoated vesicles demonstrated high stability and uniformity, with a size of 320. 1% hyaluronic acid (HA), successful surface functionalization and improved size stability was achieved. Ex vivo and confocal studies confirmed that these PEG-liposomes successfully reached the deep dermis; notably, a sequential application strategy of the coated and uncoated PEG-liposomes showed that uncoated vesicles could transiently disrupt lipid structures to facilitate deeper penetration for the HA-coated versions.
- By coating these vesicles with 0.1% hyaluronic acid (HA), successful surface functionalization and improved size stability was achieved.
- The uncoated vesicles demonstrated high stability and uniformity, with a size of 320.17 ± 0.25 nm and a zeta potential of -35.2 ± 0.4 mV.
- Ex vivo and confocal studies confirmed that these PEG-liposomes successfully reached the deep dermis; notably, a sequential application strategy of the coated and uncoated PEG-liposomes showed that uncoated vesicles could transiently disrupt lipid structures to facilitate deeper penetration for the HA-coated versions.
- The cooperative effect of this dual-vesicle system not only restored the structural integrity of the dermal-epidermal junction but also significantly outperformed existing commercial resveratrol products.
Relevant if you're working with hyaluronic acid, resveratrol, pha for aging.
What this means for your routine
If you're targeting aging, this research supports adding hyaluronic_acid to your AM/PM routine. Effective concentration range: 0.1% based on this study.
If you're targeting aging, this research supports adding resveratrol to your AM/PM routine. Effective concentration range: 0.1% based on this study.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
Technical Summary, For Professional Reference
Clinical context
1. Eur J Pharm Biopharm. 2026 Aug 5:115206. doi: 10.1016/j.ejpb.2026.115206. Online ahead of print. PEG-400-Modified transethosomes for resveratrol Delivery: Enhanced dermal penetration and collagen remodeling over Dermarolling Strategies.
Full abstract→
1. Eur J Pharm Biopharm. 2026 Aug 5:115206. doi: 10.1016/j.ejpb.2026.115206. Online ahead of print. PEG-400-Modified transethosomes for resveratrol Delivery: Enhanced dermal penetration and collagen remodeling over Dermarolling Strategies. Zoweil M(1), Aboushady D(2), Kamel AS(3), Tadros MI(4), Mansour S(5), Rady M(6). Author information: (1)Department Pharmaceutical Technology, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11865, New Cairo, Egypt; Department of Pharmaceutics, Faculty of Pharmacy and Drug Technology, Chinese University, 11771 Cairo, Egypt. (2)Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo 11856, New Cairo, Egypt. (3)Department of Pharmacology and Toxicology, Faculty of Pharmacy and Drug Technology, Chinese University, 11771 Cairo, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt. (4)Department of Pharmaceutics, Faculty of Pharmacy and Drug Technology, Chinese University, 11771 Cairo, Egypt; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt. (5)Department Pharmaceutical Technology, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11865, New Cairo, Egypt; Department Pharmaceutical Technology, Faculty of Pharmaceutical Engineering, German International University, 11841, New Administrative Capital, New Cairo, Egypt; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy Ain Shams University, 11566 Cairo, Egypt. (6)Department Pharmaceutical Technology, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11865, New Cairo, Egypt; Department Pharmaceutical Technology, Faculty of Pharmaceutical Engineering, German International University, 11841, New Administrative Capital, New Cairo, Egypt. Electronic address: mairady48@gmail.com. Skin aging is a complex biological process driven by collagen degradation and oxidative damage, often exacerbated by UV exposure. While resveratrol is a premier antioxidant for anti-aging, its topical efficacy is historically limited by poor water solubility and weak skin penetration. This study addresses these barriers by developing optimized polyethylene glycol-based liposomes (PEG-liposomes) as novel deformable liposome derivative. The uncoated vesicles demonstrated high stability and uniformity, with a size of 320.17 ± 0.25 nm and a zeta potential of -35.2 ± 0.4 mV. By coating these vesicles with 0.1% hyaluronic acid (HA), successful surface functionalization and improved size stability was achieved. Ex vivo and confocal studies confirmed that these PEG-liposomes successfully reached the deep dermis; notably, a sequential application strategy of the coated and uncoated PEG-liposomes showed that uncoated vesicles could transiently disrupt lipid structures to facilitate deeper penetration for the HA-coated versions. When integrated with micro-needling via a derma roller, the system triggered significant collagen remodeling and a surge in antioxidant enzymes like SOD, while simultaneously reducing oxidative stress markers such as MDA, MMP-1, and the aging indicator beta-galactosidase. The cooperative effect of this dual-vesicle system not only restored the structural integrity of the dermal-epidermal junction but also significantly outperformed existing commercial resveratrol products. Our findings demonstrate that this novel PEG-liposomal system provides a transformative approach to deep-tissue rejuvenation. Through its unique synergistic mechanism with micro-needling, it achieves biological remodeling and dermal restoration that surpasses the efficacy of current market-leading standards. Copyright © 2026. Published by Elsevier B.V. DOI: 10.1016/j.ejpb.2026.115206 PMID: 42556752 Conflict of interest statement: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Original source →Does Astragalus mongholicus Bunge help promote the healing of wounds? A systematic review and meta-analysis of preclinical animal studies.
Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood.
Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration.
Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.